000086286112/312024Q3falsexbrli:sharesiso4217:USDiso4217:USDxbrli:sharesalts:segmentxbrli:purealts:patentalts:debenturealts:investoralts:additionalts:officeralts:paymentalts:installmentalts:tranchealts:landlordalts:guaranteeutr:sqftalts:insurance_policyalts:trading_dayalts:consultant00008628612023-12-312024-09-2800008628612024-11-0700008628612024-09-2800008628612023-12-300000862861us-gaap:NonrelatedPartyMember2024-09-280000862861us-gaap:NonrelatedPartyMember2023-12-300000862861us-gaap:RelatedPartyMember2024-09-280000862861us-gaap:RelatedPartyMember2023-12-300000862861alts:SeriesSMember2024-09-280000862861alts:SeriesSMember2023-12-300000862861alts:SeriesA1PreferredStockMember2024-09-280000862861alts:SeriesA1PreferredStockMember2023-12-300000862861us-gaap:SeriesBMember2023-12-300000862861us-gaap:SeriesBMember2024-09-280000862861alts:SeriesMMember2023-12-300000862861alts:SeriesMMember2024-09-2800008628612024-06-302024-09-2800008628612023-07-022023-09-3000008628612023-01-012023-09-3000008628612022-12-3100008628612023-09-300000862861alts:OtherSignificantNoncashTransactionBusinessAcquisitionMember2023-12-312024-09-280000862861alts:OtherSignificantNoncashTransactionBusinessAcquisitionMember2023-01-012023-09-300000862861alts:OtherSignificantNoncashTransactionConsultingServicesMember2023-12-312024-09-280000862861alts:OtherSignificantNoncashTransactionConsultingServicesMember2023-01-012023-09-300000862861alts:OtherSignificantNoncashTransactionLiabilityObligationsMember2023-12-312024-09-280000862861alts:OtherSignificantNoncashTransactionLiabilityObligationsMember2023-01-012023-09-300000862861us-gaap:PreferredStockMemberalts:SeriesA1PreferredStockMember2023-12-300000862861us-gaap:PreferredStockMemberalts:SeriesS1PreferredMember2023-12-300000862861us-gaap:PreferredStockMemberus-gaap:SeriesBPreferredStockMember2023-12-300000862861us-gaap:PreferredStockMemberalts:SeriesMPreferredStockMember2023-12-300000862861us-gaap:CommonStockMember2023-12-300000862861us-gaap:AdditionalPaidInCapitalMember2023-12-300000862861us-gaap:RetainedEarningsMember2023-12-300000862861us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-300000862861us-gaap:AdditionalPaidInCapitalMember2023-12-312024-03-3000008628612023-12-312024-03-300000862861us-gaap:CommonStockMember2023-12-312024-03-300000862861us-gaap:RetainedEarningsMember2023-12-312024-03-300000862861us-gaap:PreferredStockMemberalts:SeriesA1PreferredStockMember2024-03-300000862861us-gaap:PreferredStockMemberalts:SeriesS1PreferredMember2024-03-300000862861us-gaap:PreferredStockMemberus-gaap:SeriesBPreferredStockMember2024-03-300000862861us-gaap:PreferredStockMemberalts:SeriesMPreferredStockMember2024-03-300000862861us-gaap:CommonStockMember2024-03-300000862861us-gaap:AdditionalPaidInCapitalMember2024-03-300000862861us-gaap:RetainedEarningsMember2024-03-300000862861us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-3000008628612024-03-300000862861us-gaap:CommonStockMember2024-03-312024-06-290000862861us-gaap:AdditionalPaidInCapitalMember2024-03-312024-06-2900008628612024-03-312024-06-290000862861us-gaap:PreferredStockMemberus-gaap:SeriesBPreferredStockMember2024-03-312024-06-290000862861us-gaap:PreferredStockMemberalts:SeriesMPreferredStockMember2024-03-312024-06-290000862861us-gaap:PreferredStockMemberalts:SeriesA1PreferredStockMember2024-03-312024-06-290000862861us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-312024-06-290000862861us-gaap:RetainedEarningsMember2024-03-312024-06-290000862861us-gaap:PreferredStockMemberalts:SeriesA1PreferredStockMember2024-06-290000862861us-gaap:PreferredStockMemberalts:SeriesS1PreferredMember2024-06-290000862861us-gaap:PreferredStockMemberus-gaap:SeriesBPreferredStockMember2024-06-290000862861us-gaap:PreferredStockMemberalts:SeriesMPreferredStockMember2024-06-290000862861us-gaap:CommonStockMember2024-06-290000862861us-gaap:AdditionalPaidInCapitalMember2024-06-290000862861us-gaap:RetainedEarningsMember2024-06-290000862861us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-2900008628612024-06-290000862861us-gaap:CommonStockMember2024-06-302024-09-280000862861us-gaap:AdditionalPaidInCapitalMember2024-06-302024-09-280000862861us-gaap:PreferredStockMemberalts:SeriesA1PreferredStockMember2024-06-302024-09-280000862861us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-302024-09-280000862861us-gaap:RetainedEarningsMember2024-06-302024-09-280000862861us-gaap:PreferredStockMemberalts:SeriesA1PreferredStockMember2024-09-280000862861us-gaap:PreferredStockMemberalts:SeriesS1PreferredMember2024-09-280000862861us-gaap:PreferredStockMemberus-gaap:SeriesBPreferredStockMember2024-09-280000862861us-gaap:PreferredStockMemberalts:SeriesMPreferredStockMember2024-09-280000862861us-gaap:CommonStockMember2024-09-280000862861us-gaap:AdditionalPaidInCapitalMember2024-09-280000862861us-gaap:RetainedEarningsMember2024-09-280000862861us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-280000862861us-gaap:PreferredStockMemberalts:SeriesA1PreferredStockMember2022-12-310000862861us-gaap:PreferredStockMemberalts:SeriesS1PreferredMember2022-12-310000862861us-gaap:CommonStockMember2022-12-310000862861us-gaap:AdditionalPaidInCapitalMember2022-12-310000862861us-gaap:RetainedEarningsMember2022-12-310000862861us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000862861us-gaap:AdditionalPaidInCapitalMember2023-01-012023-04-0100008628612023-01-012023-04-010000862861us-gaap:CommonStockMember2023-01-012023-04-010000862861us-gaap:PreferredStockMemberalts:SeriesA1PreferredStockMember2023-01-012023-04-010000862861us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-04-010000862861us-gaap:RetainedEarningsMember2023-01-012023-04-010000862861us-gaap:PreferredStockMemberalts:SeriesA1PreferredStockMember2023-04-010000862861us-gaap:PreferredStockMemberalts:SeriesS1PreferredMember2023-04-010000862861us-gaap:CommonStockMember2023-04-010000862861us-gaap:AdditionalPaidInCapitalMember2023-04-010000862861us-gaap:RetainedEarningsMember2023-04-010000862861us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-0100008628612023-04-010000862861us-gaap:AdditionalPaidInCapitalMember2023-04-022023-07-0100008628612023-04-022023-07-010000862861us-gaap:RetainedEarningsMember2023-04-022023-07-010000862861us-gaap:PreferredStockMemberalts:SeriesA1PreferredStockMember2023-07-010000862861us-gaap:PreferredStockMemberalts:SeriesS1PreferredMember2023-07-010000862861us-gaap:CommonStockMember2023-07-010000862861us-gaap:AdditionalPaidInCapitalMember2023-07-010000862861us-gaap:RetainedEarningsMember2023-07-010000862861us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-0100008628612023-07-010000862861us-gaap:AdditionalPaidInCapitalMember2023-07-022023-09-300000862861us-gaap:PreferredStockMemberalts:SeriesA1PreferredStockMember2023-07-022023-09-300000862861us-gaap:CommonStockMember2023-07-022023-09-300000862861us-gaap:RetainedEarningsMember2023-07-022023-09-300000862861us-gaap:PreferredStockMemberalts:SeriesA1PreferredStockMember2023-09-300000862861us-gaap:PreferredStockMemberalts:SeriesS1PreferredMember2023-09-300000862861us-gaap:CommonStockMember2023-09-300000862861us-gaap:AdditionalPaidInCapitalMember2023-09-300000862861us-gaap:RetainedEarningsMember2023-09-300000862861us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300000862861alts:Alt5SigmaInc.Member2024-05-152024-05-150000862861alts:Alt5SigmaInc.Member2024-05-150000862861alts:Alt5SigmaInc.Member2024-05-090000862861alts:Alt5SigmaInc.Memberus-gaap:SeriesBPreferredStockMember2024-05-152024-05-150000862861alts:Alt5SigmaInc.Memberalts:SeriesMPreferredStockMember2024-05-152024-05-150000862861alts:Alt5SigmaInc.Memberus-gaap:CommonStockMember2024-05-152024-05-150000862861alts:Alt5SigmaInc.Member2024-06-302024-09-280000862861alts:Alt5SigmaInc.Memberus-gaap:CustomerRelationshipsMember2024-05-150000862861alts:Alt5SigmaInc.Memberus-gaap:TradeNamesMember2024-05-150000862861alts:Alt5SigmaInc.Memberus-gaap:DevelopedTechnologyRightsMember2024-05-150000862861srt:ProFormaMember2024-06-302024-09-280000862861us-gaap:ScenarioAdjustmentMember2024-06-302024-09-280000862861alts:Alt5SigmaInc.Member2023-07-022023-09-300000862861srt:ProFormaMember2023-07-022023-09-300000862861us-gaap:ScenarioAdjustmentMember2023-07-022023-09-300000862861alts:Alt5SigmaInc.Member2023-12-312024-09-280000862861srt:ProFormaMember2023-12-312024-09-280000862861us-gaap:ScenarioAdjustmentMember2023-12-312024-09-280000862861alts:Alt5SigmaInc.Member2023-01-012023-09-300000862861srt:ProFormaMember2023-01-012023-09-300000862861us-gaap:ScenarioAdjustmentMember2023-01-012023-09-300000862861alts:SoinTherapeuticsLLCMemberalts:SeriesSConvertiblePreferredStockMember2024-01-242024-01-240000862861alts:SoinTherapeuticsLLCMember2024-03-012024-03-300000862861alts:SoinTherapeuticsLLCMemberalts:BusinessAcquisitionConsiderationTrancheOneMember2024-03-012024-03-300000862861alts:SoinTherapeuticsLLCMemberalts:BusinessAcquisitionConsiderationTrancheTwoMember2024-03-012024-03-300000862861alts:SoinTherapeuticsLLCMemberalts:SoinAgreementConvertibleTrancheOneMember2024-01-242024-01-240000862861alts:SoinTherapeuticsLLCMemberalts:SoinAgreementConvertibleTrancheOneMember2022-12-282022-12-280000862861alts:SoinTherapeuticsLLCMemberalts:SoinAgreementConvertibleTrancheTwoMember2024-01-242024-01-240000862861alts:SoinTherapeuticsLLCMemberalts:SoinAgreementConvertibleTrancheTwoMember2022-12-282022-12-280000862861alts:SoinTherapeuticsLLCMemberalts:SoinAgreementConvertibleTrancheThreeMember2023-12-312024-09-280000862861alts:SoinTherapeuticsLLCMemberalts:SoinAgreementConvertibleTrancheThreeMember2022-12-282022-12-280000862861alts:ARCAAndSubsidiariesMemberus-gaap:SegmentDiscontinuedOperationsMemberalts:RecyclingSegmentMember2024-06-302024-09-280000862861alts:ARCAAndSubsidiariesMemberus-gaap:SegmentDiscontinuedOperationsMemberalts:RecyclingSegmentMember2023-07-022023-09-300000862861alts:ARCAAndSubsidiariesMemberus-gaap:SegmentDiscontinuedOperationsMemberalts:RecyclingSegmentMember2023-12-312024-09-280000862861alts:ARCAAndSubsidiariesMemberus-gaap:SegmentDiscontinuedOperationsMemberalts:RecyclingSegmentMember2023-01-012023-09-300000862861alts:ARCAAndSubsidiariesMemberus-gaap:SegmentDiscontinuedOperationsMemberalts:RecyclingSegmentMember2023-12-300000862861alts:ARCAAndSubsidiariesMemberus-gaap:SegmentDiscontinuedOperationsMemberalts:RecyclingSegmentMember2022-12-310000862861alts:ARCAAndSubsidiariesMemberus-gaap:SegmentDiscontinuedOperationsMemberalts:RecyclingSegmentMember2024-09-280000862861alts:ARCAAndSubsidiariesMemberus-gaap:SegmentDiscontinuedOperationsMemberalts:RecyclingSegmentMember2023-09-300000862861alts:SpyrTechnologiesIncMember2024-09-280000862861us-gaap:AssetUnderConstructionMember2024-09-280000862861us-gaap:AssetUnderConstructionMember2023-12-300000862861alts:SoinIntangiblesMember2024-09-280000862861alts:SoinIntangiblesMember2023-12-300000862861us-gaap:CustomerRelationshipsMember2024-09-280000862861us-gaap:CustomerRelationshipsMember2023-12-300000862861us-gaap:TradeNamesMember2024-09-280000862861us-gaap:TradeNamesMember2023-12-300000862861us-gaap:DevelopedTechnologyRightsMember2024-09-280000862861us-gaap:DevelopedTechnologyRightsMember2023-12-300000862861alts:PatentsAndDomainsMember2024-09-280000862861alts:PatentsAndDomainsMember2023-12-300000862861alts:SeriesGConvertiblePreferredStockMember2023-12-300000862861alts:CommonShareEquivalentsMember2023-12-300000862861alts:SeriesGConvertiblePreferredStockMember2023-12-312024-03-300000862861alts:CommonShareEquivalentsMember2023-12-312024-03-300000862861alts:SeriesGConvertiblePreferredStockMember2024-03-300000862861alts:CommonShareEquivalentsMember2024-03-300000862861alts:SeriesGConvertiblePreferredStockMember2024-03-312024-06-290000862861alts:CommonShareEquivalentsMember2024-03-312024-06-290000862861alts:SeriesGConvertiblePreferredStockMember2024-06-290000862861alts:CommonShareEquivalentsMember2024-06-290000862861alts:SeriesGConvertiblePreferredStockMember2024-09-280000862861alts:CommonShareEquivalentsMember2024-09-280000862861alts:A12DebenturesMaturingJune302024Memberalts:DebenturesMember2023-12-300000862861alts:A12DebenturesMaturingJune302025Memberalts:DebenturesMember2024-09-280000862861alts:A12DebenturesMaturingJune302025Memberalts:DebenturesMember2023-12-300000862861alts:DebenturesMember2024-09-280000862861alts:DebenturesMember2023-12-300000862861alts:DebenturesMember2018-10-012019-09-300000862861alts:DebenturesMember2024-06-302024-09-280000862861alts:LegacySubsidiaryFixedDepositsMemberus-gaap:LongTermDebtMemberus-gaap:RelatedPartyMember2024-09-280000862861alts:LegacySubsidiaryFixedDepositsMemberus-gaap:LongTermDebtMemberus-gaap:RelatedPartyMember2023-12-300000862861alts:LegacySubsidiaryLoanMemberus-gaap:LongTermDebtMemberus-gaap:RelatedPartyMember2024-09-280000862861alts:LegacySubsidiaryLoanMemberus-gaap:LongTermDebtMemberus-gaap:RelatedPartyMember2023-12-300000862861alts:LegacyUnaffiliatedThirdPartyNotesMemberus-gaap:LongTermDebtMemberus-gaap:RelatedPartyMember2024-09-280000862861alts:LegacyUnaffiliatedThirdPartyNotesMemberus-gaap:LongTermDebtMemberus-gaap:RelatedPartyMember2023-12-300000862861alts:OtherLegacyNotesPayableMemberus-gaap:LongTermDebtMemberus-gaap:RelatedPartyMember2024-09-280000862861alts:OtherLegacyNotesPayableMemberus-gaap:LongTermDebtMemberus-gaap:RelatedPartyMember2023-12-300000862861us-gaap:RelatedPartyMemberus-gaap:LongTermDebtMember2024-09-280000862861us-gaap:RelatedPartyMemberus-gaap:LongTermDebtMember2023-12-300000862861alts:LegacySubsidiaryFixedDepositsMemberus-gaap:LongTermDebtMemberus-gaap:RelatedPartyMember2024-04-300000862861alts:IcgNoteMemberalts:PromissoryNoteMemberus-gaap:RelatedPartyMemberalts:NotesPayableWithLiveVenturesAndICGMember2024-02-070000862861alts:IcgNoteMemberalts:PromissoryNoteMemberus-gaap:RelatedPartyMemberalts:NotesPayableWithLiveVenturesAndICGMember2024-03-252024-03-250000862861alts:IcgNoteMemberalts:PromissoryNoteMemberus-gaap:RelatedPartyMemberalts:NotesPayableWithLiveVenturesAndICGMember2024-04-122024-04-120000862861alts:IcgNoteMemberalts:PromissoryNoteMemberus-gaap:RelatedPartyMemberalts:NotesPayableWithLiveVenturesAndICGMember2024-06-302024-09-280000862861alts:IcgNoteMemberalts:PromissoryNoteMemberus-gaap:RelatedPartyMemberalts:NotesPayableWithLiveVenturesAndICGMember2024-09-280000862861alts:LiveNoteMemberalts:PromissoryNoteMemberus-gaap:RelatedPartyMemberalts:NotesPayableWithLiveVenturesAndICGMember2024-02-070000862861alts:LiveNoteMemberalts:PromissoryNoteMemberus-gaap:RelatedPartyMemberalts:NotesPayableWithLiveVenturesAndICGMember2024-03-222024-03-220000862861alts:LiveNoteMemberalts:PromissoryNoteMemberus-gaap:RelatedPartyMemberalts:NotesPayableWithLiveVenturesAndICGMember2024-04-102024-04-100000862861alts:LiveNoteMemberalts:PromissoryNoteMemberus-gaap:RelatedPartyMemberalts:NotesPayableWithLiveVenturesAndICGMember2024-09-280000862861alts:NonConvertibleDebentureBigDebentureMemberus-gaap:UnsecuredDebtMember2024-08-200000862861alts:NonConvertibleDebentureBigDebentureMemberus-gaap:UnsecuredDebtMemberalts:InvestorOneMember2024-08-200000862861alts:BigWarrantMemberalts:InvestorOneMember2024-08-200000862861alts:NonConvertibleDebentureSmallDebentureMemberus-gaap:UnsecuredDebtMemberalts:InvestorTwoAndInvestorThreeMember2024-08-200000862861us-gaap:WarrantMemberalts:InvestorTwoAndInvestorThreeMember2024-08-200000862861alts:DebtInstrumentCovenantPeriodPeriodOneMemberalts:NonConvertibleDebentureBigAndSmallDebentureMemberus-gaap:UnsecuredDebtMember2024-08-200000862861alts:DebtInstrumentCovenantPeriodPeriodTwoMemberalts:NonConvertibleDebentureBigAndSmallDebentureMemberus-gaap:UnsecuredDebtMember2024-08-200000862861alts:DebtInstrumentCovenantPeriodPeriodThreeMemberalts:NonConvertibleDebentureBigAndSmallDebentureMemberus-gaap:UnsecuredDebtMember2024-08-200000862861alts:NonConvertibleDebentureBigDebentureMemberus-gaap:UnsecuredDebtMemberalts:DebtInstrumentOriginalIssueDiscountExpansionOneMember2024-08-200000862861alts:NonConvertibleDebentureBigDebentureMemberus-gaap:UnsecuredDebtMemberalts:DebtInstrumentOriginalIssueDiscountExpansionTwoMember2024-08-200000862861alts:NonConvertibleDebentureSmallDebentureMemberus-gaap:UnsecuredDebtMember2024-08-200000862861alts:NonConvertibleDebentureSmallDebentureMemberus-gaap:UnsecuredDebtMemberalts:DebtInstrumentOriginalIssueDiscountExpansionOneMember2024-08-200000862861alts:NonConvertibleDebentureSmallDebentureMemberus-gaap:UnsecuredDebtMemberalts:DebtInstrumentOriginalIssueDiscountExpansionTwoMember2024-08-200000862861alts:BigWarrantMember2024-08-200000862861alts:BigWarrantMemberalts:DebtInstrumentCovenantPeriodPeriodOneMember2024-08-200000862861alts:BigWarrantMemberalts:DebtInstrumentCovenantPeriodPeriodTwoMember2024-08-200000862861alts:BigWarrantMemberalts:DebtInstrumentCovenantPeriodPeriodThreeMember2024-08-200000862861alts:SmallWarrantMember2024-08-200000862861alts:SmallWarrantMemberalts:DebtInstrumentCovenantPeriodPeriodOneMember2024-08-200000862861alts:SmallWarrantMemberalts:DebtInstrumentCovenantPeriodPeriodTwoMember2024-08-200000862861alts:SmallWarrantMemberalts:DebtInstrumentCovenantPeriodPeriodThreeMember2024-08-2000008628612024-08-202024-08-200000862861alts:NonConvertibleDebentureBigAndSmallDebentureMemberus-gaap:UnsecuredDebtMember2024-09-280000862861alts:FixedDepositAgreementMemberus-gaap:LongTermDebtMemberalts:ALT5SubsidiaryMember2024-09-192024-09-190000862861alts:FixedDepositAgreementMemberus-gaap:LongTermDebtMemberalts:ALT5SubsidiaryMember2024-09-190000862861alts:FixedDepositAgreementMemberus-gaap:LongTermDebtMemberalts:ALT5SubsidiaryMember2024-09-280000862861alts:IsaacCapitalGroupNoteMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMember2024-09-280000862861alts:IsaacCapitalGroupNoteMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMember2023-12-300000862861alts:NotePayableToIsaacCapitalGroupMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMember2024-09-280000862861alts:NotePayableToIsaacCapitalGroupMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMember2023-12-300000862861alts:NotePayableToIsaacCapitalGroupMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMemberalts:NotesPayableWithLiveVenturesAndICGMember2024-02-070000862861alts:NotePayableToLiveVentureIncorporatedMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMember2024-02-070000862861alts:NotePayableToLiveVentureIncorporatedMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMember2023-12-300000862861alts:NotePayableToLiveVentureIncorporatedMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMember2024-09-280000862861alts:A10ConvertiblePromissoryNoteMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMemberalts:IsaacConsultingAgreementMember2024-03-040000862861alts:A10ConvertiblePromissoryNoteMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMemberalts:IsaacConsultingAgreementMember2024-09-280000862861alts:A10ConvertiblePromissoryNoteMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMemberalts:IsaacConsultingAgreementMember2023-12-300000862861alts:NotePayableToJonIsaacConsultingAgreementMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMember2024-09-280000862861alts:NotePayableToJonIsaacConsultingAgreementMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMember2023-12-300000862861alts:IsaacCapitalGroupShortTermDemandAdvanceMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMemberalts:IcgNoteMember2024-04-180000862861alts:IsaacCapitalGroupShortTermDemandAdvanceMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMemberalts:IcgNoteMember2023-12-300000862861alts:IsaacCapitalGroupShortTermDemandAdvanceMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMemberalts:IcgNoteMember2024-09-280000862861alts:IsaacCapitalGroupShortTermDemandAdvanceMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMember2024-09-280000862861alts:IsaacCapitalGroupShortTermDemandAdvanceMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMember2023-12-300000862861us-gaap:RelatedPartyMemberalts:NovalkAppsSAALLPMemberalts:RelatedPartyTransactionShortTermAdvancesMember2024-05-280000862861us-gaap:RelatedPartyMemberalts:NovalkAppsSAALLPMemberalts:RelatedPartyTransactionShortTermAdvancesMember2024-06-030000862861us-gaap:RelatedPartyMemberalts:NovalkAppsSAALLPMemberalts:RelatedPartyTransactionShortTermAdvancesMember2023-12-300000862861us-gaap:RelatedPartyMemberalts:NovalkAppsSAALLPMemberalts:RelatedPartyTransactionShortTermAdvancesMember2024-09-280000862861alts:NovalkAppsSAALLPShortTermDemandAdvanceMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMember2024-09-280000862861alts:NovalkAppsSAALLPShortTermDemandAdvanceMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMember2023-12-300000862861us-gaap:RelatedPartyMemberus-gaap:NotesPayableOtherPayablesMember2024-09-280000862861us-gaap:RelatedPartyMemberus-gaap:NotesPayableOtherPayablesMember2023-12-300000862861alts:NotesPayableRelatedPartiesMemberus-gaap:RelatedPartyMember2024-09-280000862861alts:IcgNoteMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMemberalts:IcgNoteMember2024-02-070000862861alts:IcgNoteMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMemberalts:IcgNoteMember2024-03-252024-03-250000862861alts:IcgNoteMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMemberus-gaap:EquityUnitPurchaseAgreementsMemberalts:IcgNoteMember2024-03-252024-03-250000862861alts:IcgNoteMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMemberalts:IcgNoteMember2024-09-280000862861alts:IsaacCapitalGroupShortTermDemandAdvanceMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMemberalts:IcgNoteMember2024-04-182024-04-180000862861alts:LiveNoteMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMemberalts:LiveVentureIncorporatedMember2024-02-070000862861alts:LiveNoteMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMemberalts:LiveVentureIncorporatedMember2024-03-222024-03-220000862861alts:LiveNoteMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMemberus-gaap:EquityUnitPurchaseAgreementsMemberalts:LiveVentureIncorporatedMember2024-03-222024-03-220000862861alts:LiveNoteMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMemberalts:LiveVentureIncorporatedMember2024-09-280000862861alts:A10ConvertiblePromissoryNoteMemberus-gaap:RelatedPartyMemberalts:Mr.JonIsaacMemberalts:IsaacConsultingAgreementMember2024-03-042024-03-040000862861alts:A10ConvertiblePromissoryNoteMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMemberalts:IsaacConsultingAgreementMember2024-03-042024-03-040000862861us-gaap:RelatedPartyMemberalts:Mr.JonIsaacMemberalts:IsaacConsultingAgreementMember2024-03-040000862861us-gaap:RelatedPartyMemberalts:Mr.JonIsaacMemberalts:IsaacConsultingAgreementMember2024-09-280000862861us-gaap:RelatedPartyMemberalts:NovalkAppsSAALLPMemberalts:RelatedPartyTransactionShortTermAdvancesMember2024-05-282024-05-280000862861us-gaap:RelatedPartyMemberalts:NovalkAppsSAALLPMemberalts:RelatedPartyTransactionShortTermAdvancesMember2024-06-032024-06-030000862861us-gaap:RelatedPartyMemberalts:Mr.TonyIsaacMemberalts:RelatedPartyTransactionShortTermAdvancesMember2024-06-032024-06-030000862861us-gaap:RelatedPartyMemberalts:Mr.TonyIsaacMemberalts:RelatedPartyTransactionShortTermAdvancesMember2023-12-300000862861us-gaap:RelatedPartyMemberalts:Mr.TonyIsaacMemberalts:RelatedPartyTransactionShortTermAdvancesMember2024-06-030000862861us-gaap:RelatedPartyMemberalts:Mr.TonyIsaacMemberalts:RelatedPartyTransactionShortTermAdvancesMember2024-09-280000862861alts:SECComplaintMember2021-08-020000862861alts:SECComplaintMember2024-05-282024-05-280000862861alts:SECComplaintMember2024-05-280000862861alts:SkybridgeLitigationMemberalts:SkyBridgeAmericasMember2021-02-012021-02-010000862861alts:InterestFeesAndCostsAndAttorneysFeesMemberalts:SkybridgeLitigationMemberalts:SkyBridgeAmericasMember2021-02-012021-02-010000862861alts:StatutoryInterestMemberalts:SkybridgeLitigationMemberalts:SkyBridgeAmericasMember2023-12-312024-09-280000862861alts:SkybridgeLitigationMemberalts:SkyBridgeAmericasMember2024-04-102024-04-100000862861alts:LegalFeesMemberalts:SkybridgeLitigationMemberalts:SkyBridgeAmericasMember2024-04-102024-04-100000862861alts:SkybridgeLitigationMemberalts:PromissoryNoteMember2024-04-100000862861alts:GeoTraqLitigationMemberalts:GeoTraqIncMember2021-04-092021-04-090000862861alts:GeoTraqLitigationMember2021-06-012021-06-010000862861alts:GeoTraqLitigationMemberalts:GeoTraqIncMember2021-06-012021-06-010000862861alts:GeoTraqLitigationMemberalts:SeriesA1PreferredStockMember2023-03-172023-03-170000862861alts:GeoTraqLitigationMemberalts:GeoTraqIncMember2023-03-172023-03-170000862861alts:GeoTraqLitigationMemberalts:SeriesA1PreferredStockMember2023-06-012023-06-010000862861alts:GeoTraqLitigationMemberus-gaap:CommonStockMember2023-06-012023-06-010000862861alts:GeoTraqLitigationMemberalts:SeriesA1PreferredStockMember2023-09-012023-09-010000862861alts:GeoTraqLitigationMemberus-gaap:CommonStockMember2023-09-012023-09-010000862861alts:GeoTraqLitigationMemberalts:SeriesA1PreferredStockMember2023-09-302023-09-300000862861alts:AlixpartnersLLCLitigationMemberalts:AlixpartnersLLCMember2022-10-192022-10-190000862861alts:AlixpartnersLLCLitigationMemberalts:AlixpartnersLLCMember2023-12-312024-09-280000862861alts:AlixpartnersLLCLitigationMemberalts:AlixpartnersLLCMember2024-09-280000862861alts:Main270LLCLitigationMemberalts:TrusteesMain270LlcMember2023-12-312024-09-280000862861alts:ApplianceSmartIncMemberalts:Main270LLCLitigationMemberalts:TrusteesMain270LlcMember2023-12-312024-09-280000862861alts:WestervilleSquareLitigationMemberalts:WestervilleSquareMember2023-12-312024-09-280000862861alts:WestervilleSquareLitigationMemberalts:WestervilleSquareMember2023-06-042023-06-040000862861alts:OtherCommitmentsAndLitigationCasesMemberalts:ApplianceSmartIncMember2021-01-020000862861alts:OtherCommitmentsAndLitigationCasesMember2017-12-300000862861alts:OtherCommitmentsAndLitigationCasesMemberalts:ApplianceSmartIncMember2023-12-300000862861alts:OtherCommitmentsAndLitigationCasesMember2023-12-300000862861alts:ArticlesOfIncorporationMember2024-09-280000862861us-gaap:PrivatePlacementMember2023-08-182023-08-180000862861us-gaap:PrivatePlacementMember2023-08-180000862861alts:PreFundedWarrantsMemberus-gaap:PrivatePlacementMember2023-08-180000862861us-gaap:PrivatePlacementMember2023-12-312024-03-300000862861us-gaap:RestrictedStockUnitsRSUMemberalts:A2023EquityIncentivePlanMember2023-12-312024-09-280000862861us-gaap:RestrictedStockUnitsRSUMemberalts:A2023EquityIncentivePlanMember2023-12-312024-03-300000862861us-gaap:RestrictedStockUnitsRSUMemberalts:A2023EquityIncentivePlanMember2023-10-092023-10-090000862861us-gaap:RestrictedStockUnitsRSUMemberalts:A2023EquityIncentivePlanMember2023-10-090000862861us-gaap:RelatedPartyMemberus-gaap:EquityUnitPurchaseAgreementsMemberalts:IcgNoteMember2024-02-230000862861us-gaap:RelatedPartyMemberus-gaap:EquityUnitPurchaseAgreementsMember2024-02-232024-02-230000862861us-gaap:RelatedPartyMemberus-gaap:EquityUnitPurchaseAgreementsMemberalts:IcgNoteMember2024-02-232024-02-230000862861us-gaap:RelatedPartyMemberalts:ThirdPartyExchangeForBrokerageServicesMember2024-02-232024-02-230000862861us-gaap:RelatedPartyMemberalts:Mr.JonIsaacMemberalts:IsaacConsultingAgreementMember2024-03-042024-03-040000862861alts:IcgNoteMemberalts:PromissoryNoteMemberus-gaap:RelatedPartyMemberalts:IcgNoteMember2024-03-222024-03-220000862861alts:IcgNoteMemberalts:PromissoryNoteMemberus-gaap:RelatedPartyMemberus-gaap:EquityUnitPurchaseAgreementsMemberalts:IcgNoteMember2024-03-222024-03-220000862861alts:IcgNoteMemberalts:PromissoryNoteMemberus-gaap:RelatedPartyMemberalts:IcgNoteMember2024-03-252024-03-250000862861alts:IcgNoteMemberalts:PromissoryNoteMemberus-gaap:RelatedPartyMemberus-gaap:EquityUnitPurchaseAgreementsMemberalts:IcgNoteMember2024-03-252024-03-250000862861alts:IcgNoteMemberalts:PromissoryNoteMemberus-gaap:RelatedPartyMemberalts:IcgNoteMember2024-04-102024-04-100000862861alts:IcgNoteMemberalts:PromissoryNoteMemberus-gaap:RelatedPartyMemberus-gaap:EquityUnitPurchaseAgreementsMemberalts:IcgNoteMember2024-04-102024-04-100000862861alts:IcgNoteMemberalts:PromissoryNoteMemberus-gaap:RelatedPartyMemberalts:IcgNoteMember2024-04-122024-04-120000862861alts:IcgNoteMemberalts:PromissoryNoteMemberus-gaap:RelatedPartyMemberus-gaap:EquityUnitPurchaseAgreementsMemberalts:IcgNoteMember2024-04-122024-04-120000862861us-gaap:RestrictedStockUnitsRSUMemberus-gaap:RelatedPartyMemberus-gaap:CommonStockMemberalts:NorthYorkLTDMember2024-03-042024-03-040000862861us-gaap:RelatedPartyMemberalts:SeriesVConvertiblePreferredStockMemberalts:NorthYorkLTDMember2024-03-042024-03-040000862861us-gaap:RelatedPartyMemberalts:NorthYorkLTDMember2024-03-040000862861us-gaap:RelatedPartyMemberalts:NorthYorkLTDMember2024-03-042024-03-040000862861us-gaap:RelatedPartyMemberus-gaap:EquityUnitPurchaseAgreementsMemberalts:IcgNoteMember2024-05-010000862861us-gaap:RelatedPartyMemberus-gaap:EquityUnitPurchaseAgreementsMember2024-05-012024-05-010000862861us-gaap:RelatedPartyMemberus-gaap:EquityUnitPurchaseAgreementsMemberalts:IcgNoteMember2024-05-012024-05-010000862861us-gaap:RelatedPartyMemberalts:IsaacConsultingAgreementMember2024-06-032024-06-030000862861us-gaap:RelatedPartyMemberalts:IsaacConsultingAgreementMember2024-06-062024-06-060000862861alts:A2023EquityIncentivePlanMemberus-gaap:RelatedPartyMember2024-06-302024-09-280000862861alts:A2023EquityIncentivePlanMember2024-09-280000862861us-gaap:RestrictedStockUnitsRSUMemberalts:A2023EquityIncentivePlanMember2024-06-302024-09-280000862861alts:A2023EquityIncentivePlanMemberus-gaap:RelatedPartyMember2023-12-312024-09-280000862861alts:Plan2016Member2020-11-030000862861alts:Plan2016Member2020-11-040000862861alts:Plan2016Member2024-09-280000862861alts:Plan2016Member2023-12-300000862861alts:Plan2011Member2024-09-280000862861alts:Plan2011Member2023-12-300000862861alts:Plan2011Member2023-12-312024-09-2800008628612023-01-012023-12-300000862861us-gaap:EmployeeStockOptionMember2024-06-302024-09-280000862861us-gaap:EmployeeStockOptionMember2023-07-022023-09-300000862861us-gaap:EmployeeStockOptionMember2023-12-312024-09-280000862861us-gaap:EmployeeStockOptionMember2023-01-012023-09-300000862861us-gaap:EmployeeStockOptionMember2024-09-280000862861alts:SeriesA1PreferredStockMember2023-12-312024-09-280000862861alts:SoinTherapeuticsMemberalts:SeriesSConvertiblePreferredStockMember2022-12-280000862861alts:SoinTherapeuticsMemberalts:SeriesSConvertiblePreferredStockMember2022-12-282022-12-280000862861alts:SeriesSConvertiblePreferredStockMember2024-09-280000862861alts:SeriesSConvertiblePreferredStockMember2023-12-300000862861us-gaap:PreferredStockMemberalts:SeriesSPreferredStocksMember2023-12-312024-09-280000862861us-gaap:PreferredStockMemberalts:SeriesSPreferredStocksMember2024-09-280000862861us-gaap:SegmentDiscontinuedOperationsMember2024-06-302024-09-280000862861us-gaap:SegmentDiscontinuedOperationsMember2023-07-022023-09-300000862861us-gaap:SegmentDiscontinuedOperationsMember2023-12-312024-09-280000862861us-gaap:SegmentDiscontinuedOperationsMember2023-01-012023-09-300000862861alts:BiotechnologyMember2024-06-302024-09-280000862861alts:BiotechnologyMember2023-07-022023-09-300000862861alts:BiotechnologyMember2023-12-312024-09-280000862861alts:BiotechnologyMember2023-01-012023-09-300000862861alts:FintechMember2024-06-302024-09-280000862861alts:FintechMember2023-07-022023-09-300000862861alts:FintechMember2023-12-312024-09-280000862861alts:FintechMember2023-01-012023-09-300000862861alts:RecyclingSegmentMemberus-gaap:SegmentDiscontinuedOperationsMember2024-06-302024-09-280000862861alts:RecyclingSegmentMemberus-gaap:SegmentDiscontinuedOperationsMember2023-07-022023-09-300000862861alts:RecyclingSegmentMemberus-gaap:SegmentDiscontinuedOperationsMember2023-12-312024-09-280000862861alts:RecyclingSegmentMemberus-gaap:SegmentDiscontinuedOperationsMember2023-01-012023-09-300000862861alts:ContinuingOperationsAndDiscontinuingOperationsMemberMember2024-06-302024-09-280000862861alts:ContinuingOperationsAndDiscontinuingOperationsMemberMember2023-07-022023-09-300000862861alts:ContinuingOperationsAndDiscontinuingOperationsMemberMember2023-12-312024-09-280000862861alts:ContinuingOperationsAndDiscontinuingOperationsMemberMember2023-01-012023-09-300000862861us-gaap:RelatedPartyMemberalts:LiveVenturesIncorporatedMember2024-06-302024-09-280000862861us-gaap:RelatedPartyMemberalts:LiveVenturesIncorporatedMember2023-07-022023-09-300000862861us-gaap:RelatedPartyMemberalts:LiveVenturesIncorporatedMember2023-12-312024-09-280000862861us-gaap:RelatedPartyMemberalts:LiveVenturesIncorporatedMember2023-01-012023-09-300000862861us-gaap:RelatedPartyMemberalts:LiveVenturesIncorporatedMember2024-09-280000862861alts:LiveVenturesAndICGNotesMemberalts:PromissoryNoteMemberus-gaap:RelatedPartyMemberalts:NotesPayableWithLiveVenturesAndICGMember2024-02-070000862861alts:LiveVenturesAndICGNotesMemberalts:PromissoryNoteMemberus-gaap:RelatedPartyMemberalts:NotesPayableWithLiveVenturesAndICGMember2024-02-072024-02-070000862861alts:LiveVenturesAndICGNotesMemberalts:PromissoryNoteMemberus-gaap:RelatedPartyMemberalts:NotesPayableWithLiveVenturesAndICGMember2024-09-280000862861us-gaap:RelatedPartyMemberalts:Mr.JonIsaacMemberalts:UniversalLifeInsurancePolicyPolicyOneMemberalts:IsaacConsultingAgreementMember2024-03-040000862861us-gaap:RelatedPartyMemberalts:Mr.JonIsaacMemberalts:UniversalLifeInsurancePolicyPolicyTwoMemberalts:IsaacConsultingAgreementMember2024-03-040000862861us-gaap:RelatedPartyMemberalts:Mr.JonIsaacMemberalts:IsaacConsultingAgreementMember2023-12-312024-09-280000862861us-gaap:RelatedPartyMemberus-gaap:SubsequentEventMemberalts:AcquisitionOfAssetsMember2024-11-080000862861us-gaap:RelatedPartyMemberalts:SeriesQConvertiblePreferredStockMemberus-gaap:SubsequentEventMemberalts:AcquisitionOfAssetsMember2024-11-082024-11-080000862861us-gaap:RelatedPartyMemberalts:SeriesQConvertiblePreferredStockMemberus-gaap:SubsequentEventMemberalts:AcquisitionOfAssetsMember2024-11-080000862861us-gaap:RelatedPartyMemberus-gaap:SubsequentEventMemberalts:SellingEntitiesConsultantsMemberalts:ConsultingAgreementsWithSellingEntitiesConsultantsMember2024-11-082024-11-080000862861us-gaap:RelatedPartyMemberalts:SeriesQConvertiblePreferredStockMemberus-gaap:SubsequentEventMemberalts:ConsultantOneMemberalts:ConsultingAgreementsWithSellingEntitiesConsultantsMember2024-11-082024-11-080000862861us-gaap:RelatedPartyMemberus-gaap:SubsequentEventMemberalts:ConsultantOneMemberalts:ConsultingAgreementsWithSellingEntitiesConsultantsMember2024-11-080000862861us-gaap:RelatedPartyMemberus-gaap:SubsequentEventMemberalts:ConsultantTwoMemberalts:ConsultingAgreementsWithSellingEntitiesConsultantsMember2024-11-08
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
    Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the quarterly period ended September 28, 2024
or
o    Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Commission File No. 0-19621
ALT5 Sigma Corporation
(Exact name of registrant as specified in its charter)
Nevada
(State or other jurisdiction of
incorporation or organization)
41-1454591
(I.R.S. Employer
Identification No.)
325 E. Warm Springs Road, Suite 102
Las Vegas, Nevada
(Address of principal executive offices)
89119
(Zip Code)
702-997-5968
(Registrant’s telephone number, including area code)
JanOne Inc.
(Former Name or Former Address, if Changed Since Last Report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.001 par value per share
ALTS
The Nasdaq Stock Market LLC
(The Nasdaq Capital Market)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. x Yes o No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). x Yes o No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one)
Large accelerated fileroAccelerated filero
Non-accelerated filerxSmaller reporting companyx
Emerging growth companyo
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). o Yes x No
As of November 7, 2024, there were 14,069,469 outstanding shares of the registrant’s common stock, with a par value of $0.001.


Table of Contents
ALT5 SIGMA CORPORATION
INDEX TO FORM 10-Q
Page
2

Table of Contents
PART I. FINANCIAL INFORMATION
ITEM 1. Condensed Consolidated Financial Statements
ALT5 SIGMA CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(Dollars in thousands, except per-share amounts)
September 28,
2024
December 30,
2023
(Unaudited)
Assets
Cash and cash equivalents$8,669 $5 
Trade and other receivables, net903 266 
Digital assets receivable20,888  
Prepaid expenses and other current assets1,437 75 
Total current assets31,897 346 
Property and equipment, net1,170  
Right of use assets120  
Marketable securities 286 
Deposits and other assets 9 
Intangible assets, net33,977 17,846 
Goodwill7,724  
Total assets$74,888 $18,487 
Liabilities and Stockholders' Equity
Liabilities:
Accounts payable$2,879 $2,272 
Accrued liabilities3,801 3,633 
Digital assets payable28,834  
Due to Soin2,850  
Convertible debentures563  
Operating lease liabilities26  
Notes payable2,577  
Related party notes payable and advances798  
Total current liabilities42,328 5,905 
Deferred income taxes, net1,161 639 
Related party notes payable529 707 
Notes payable6,695  
Operating lease liabilities94  
Other noncurrent liabilities 34 
Total liabilities50,807 7,285 
Commitments and contingencies (Note 16)
Mezzanine equity
Convertible preferred stock, series S - par value $0.001 per share, 200,000 authorized, 100,000 and 100,000 shares issued and outstanding at September 28, 2024 and December 30, 2023, respectively
3,856 14,510 
Stockholders' equity:
Preferred stock, series A-1 - par value $0.001 per share, 2,000,000 authorized, 23,480 and 193,730 shares issued and outstanding at September 28, 2024 and December 30, 2023, respectively
  
Preferred stock, series B - par value $0.001 per share, 34,250 authorized, 34,207 and 0 shares issued and outstanding at September 28, 2024 and December 30, 2023, respectively
8,552  
Preferred stock, series M - par value $0.001 per share, 3,200 authorized, 3,200 and 0 shares issued and outstanding at September 28, 2024 and December 30, 2023, respectively
  
Convertible preferred stock, series S - par value $0.001 per share, 200,000 authorized, 100,000 and 100,000 shares issued and outstanding at September 28, 2024 and December 30, 2023, respectively
7,993  
Common stock, par value $0.001 per share, 200,000,000 shares authorized, 14,019,015 and 4,957,647 shares issued and outstanding at September 28, 2024 and at December 30, 2023, respectively
7 3 
Accumulated other comprehensive deficit(2,995) 
Additional paid-in capital59,679 47,323 
Accumulated deficit(53,011)(50,634)
Total stockholders' equity (deficit)20,225 (3,308)
Total liabilities and stockholders' equity$74,888 $18,487 
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
3

Table of Contents
ALT5 SIGMA CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME
(UNAUDITED)
(Dollars in thousands, except per-share)
For the Thirteen Weeks Ended For the Thirty-Nine Weeks Ended
September 28,
2024
September 30,
2023
September 28,
2024
September 30,
2023
Revenues$4,941 $ $7,110 $ 
Cost of revenues2,580  3,651  
Gross profit2,361  3,459  
Operating expenses:
Selling, general and administrative expenses3,582 764 9,402 2,923 
Operating loss(1,221)(764)(5,943)(2,923)
Other income (expense):
Interest income, net253 758 5 1,598 
Unrealized loss on marketable securities(688)(267)(1,058)(514)
Unrealized (loss) gain on exchange transactions(30) 431  
Realized gain on exchange transactions391  631  
Other (loss) income, net(44)6 114 745 
Total other (loss) income, net(118)497 123 1,829 
Loss from continuing operations before provision for income taxes(1,339)(267)(5,820)(1,094)
Income tax benefit(517)(25)(3,443)(269)
Net loss from continuing operations(822)(242)(2,377)(825)
Gain from discontinued operations   13,976 
Income tax provision (benefit) for discontinued operations (28) 3,158 
Net income from discontinued operations 28  10,818 
Net (loss) income$(822)$(214)$(2,377)$9,993 
Net income (loss) per share:
Net income (loss) per share from continuing operations, basic$(0.06)$(0.06)$(0.24)$(0.22)
Net income (loss) per share from continuing operations, diluted$(0.06)$(0.06)$(0.24)$(0.22)
Net income per share from discontinued operations, basic$ $0.01 $ $2.93 
Net income per share from discontinued operations, diluted$ $0.01 $ $2.93 
Net income per share, basic$(0.06)$(0.05)$(0.24)$2.71 
Net income per share, diluted$(0.06)$(0.05)$(0.24)$2.71 
Weighted average common shares outstanding:
Basic12,805,7184,198,94010,030,6083,687,986
Diluted12,805,7184,198,94010,030,6083,687,986
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
4

Table of Contents
ALT5 SIGMA CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
(In thousands)
For the Thirty-Nine Weeks Ended
September 28, 2024September 30, 2023
OPERATING ACTIVITIES:
Net loss from continuing operations$(2,377)$(825)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization2,319 1,090 
Charge in reserve for uncollectible accounts254  
Stock based compensation expense1,507 14 
Related party notes issued for shared services600  
Accretion of note receivable discount (1,021)
Amortization of ROU asset14  
Unrealized gain on marketable securities1,058 514 
Unrealized loss on digital assets(431) 
Change in deferred tax liability(3,353) 
Changes in assets and liabilities:
Accounts receivable, net of acquisitions and dispositions1,303 506 
Digital assets receivable(11,060) 
Prepaid expenses and other current assets, net of dispositions483 309 
Digital assets payable12,071  
Accounts payable and accrued expenses, net of dispositions1,331 (689)
Other Assets10 (346)
Operating cash flows provided by discontinued operations 2,320 
Net cash provided by operating activities3,729 1,872 
INVESTING ACTIVITIES:
Cash acquired in Alt5 Subsidiary acquisition5,853  
Investing cash flows used in discontinued operations (156)
Net cash provided by (used in) investing activities5,853 (156)
FINANCING ACTIVITIES:
Proceeds from equity financing, net851 792 
Proceeds from the issuance of notes payable3,100  
Proceeds from related parties603  
Warrants exercised 259 
Payments on notes payable(2,229)(274)
Payments on related party notes payable(248) 
Financing cash flows from discontinued operations (2,212)
Net cash provided by (used in) financing activities2,077 (1,435)
Effect of changes in exchange rate on cash and cash equivalents(2,995)17 
INCREASE IN CASH AND CASH EQUIVALENTS8,664 298 
CASH AND CASH EQUIVALENTS, beginning of period5 115 
CASH AND CASH EQUIVALENTS, end of period$8,669 $413 
Supplemental cash flow disclosures:
Interest paid$ $118 
Income taxes paid  
Noncash recognition of new leases134  
Noncash financing and investing activities:
Stock issued for the acquisition of Alt5 Subsidiary$16,000 $ 
Common stock issued for consulting services853  
Common stock issued for liability obligations367  
Notes payable converted to common stock467  
Common stock issued for property and equipment1,170  
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
5

Table of Contents
ALT5 SIGMA CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)
(UNAUDITED)
(Dollars in thousands)
Series A-1 PreferredSeries S-1 PreferredSeries B PreferredSeries M PreferredCommon StockAdditional
Paid-in
Capital
Accumulated
Deficit
Accumulated
Other
Comprehensive
Deficit
Total
Stockholders'
Equity
SharesAmountSharesAmountSharesAmountSharesAmountSharesAmount
Balance, December 30, 2023193,730$ 100,000$ $ 4,957,647$3 $47,323 $(50,634)$ $(3,308)
Share based compensation— — — — — 345 — — 345 
Reclassification of Series S stock to liability— — — — — (339)— — (339)
Reclassification of Series S stock to permanent equity— — — — — — — — 7,993 
Common stock issued for equity financing— — — — 884,8801 626 — — 627 
Common stock issued for consulting agreement— — — — 200,000— 232 — — 232 
Common stock issued in lieu of notes payable obligation— — — — 600,0001 366 — — 367 
Common stock issued for RSU's granted— — — — 908,852— — — — — 
Net income— — — — — — (2,144)— (2,144)
Balance, March 30, 2024193,730 100,000   7,551,3795 48,553 (52,778) 3,773 
Share based compensation— — 295,0001,1611,161 
Common stock issued for acquisition of Alt5 Subsidiary— — 1,799,1151 7,4477,448 
Series B preferred stock issued for acquisition of Alt5 Subsidiary34,2078,552 3,200— 8,552 
Conversion of note receivable to common stock— — 200,000122122 
Common stock issued for equity financing— — 120,598342342 
Conversion of Series A-1 to common stock(123,750)— — 2,125,000— 
Common stock issued for consulting agreement— — 197,9231,000579580 
Common stock issued for property and equipment— — 300,0001,1701,170 
Foreign currency adjustment— — (807)(807)
Net income589589 
Balance, June 29, 202469,980 100,000 34,2078,552 3,200 12,589,0157 59,374 (52,189)(807)22,930 
Conversion of notes payable to common stock— — 500,000$305 305 
Conversion of Series A-1 to common stock(46,500)— — 930,000— 
Foreign currency adjustment— — — — (2,188)(2,188)
Net income— — — — $(822)(822)
Balance, September 28, 202423,48023480$ 0100,000100000$ 34,20734207$8,552 3,2003200$ 14,019,015$7 $59,679 $(53,011)$(2,995)$20,225 
6

Table of Contents
Series A-1 PreferredSeries S-1 PreferredCommon StockAdditional
Paid-in
Capital
Accumulated
Deficit
Accumulated
Other
Comprehensive
Deficit
Total
Stockholders'
Deficit
SharesAmountSharesAmountSharesAmount
Balance, December 31, 2022222,588$ 100,000$ 3,150,230$2 $45,748 $(42,822)$(621)$2,307 
Share based compensation— — — 8 — — 8 
Common stock issued for equity financing— — 361,0001 368 — — 369 
Series A-1 Preferred converted for legal settlement(5,185)— — 103,707— 170 — — 170 
Other comprehensive income— — — — — 621 621 
Net Income— — — — 10,085 — 10,085 
Balance, April 1, 2023217,403100,0003,614,9373 46,294 (32,737) 13,560 
Share based compensation$— $— $— $5 $— $— 5 
Net Income$— $— $— $— $123 $— 123 
Balance, July 1, 2023217,403217403 100,000 3,614,9373 46,299 (32,614) 13,688 
Share based compensation— — — 1 — — 1 
Series A-1 Preferred Stock converted for legal settlement(22,168)— — 443,362— 340 — — 340 
Series A-1 Preferred Stock forfeited(1,505)— — — — — — — 
Warrants exercised— — 481,348— 259 — — 259 
Common stock issued for equity financing— — 418,000— 424 — — 424 
Net Income— — — — (214)— (214)
Balance, September 30, 2023193,730193730$ 0100,000$ 4,957,647$3 $47,323 $(32,828)$ $14,498 
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
7

Table of Contents

Note 1: Background
The accompanying consolidated financial statements include the accounts of ALT5 Sigma Corporation, a Nevada corporation, and its subsidiaries (collectively, the “Company” or “ALT5”). Effective July 15, 2024, the Company changed its corporate name from “JanOne Inc.” to “ALT5 Sigma Corporation,” and also changed its Nasdaq common stock ticker symbol from “JAN” to “ALTS”. The corporate name change was effected through a parent/subsidiary short-form merger of ALT5 Sigma Corporation, the Company’s wholly-owned Nevada subsidiary formed solely for the purpose of effectuating the name change), whereby it merged with and into the Company, with the Company being the surviving entity, albeit with its new name.
The Company had three operating segments – Biotechnology, Fintech, and Recycling. In connection with the sale of ARCA Recycling, Inc. (“ARCA Recycling”), the accounts for the Recycling segment have been presented as discontinued operations in the accompanying consolidated financial statements.
Biotechnology
During September 2019, ALT5 Sigma Corporation, through its biotechnology segment, broadened its business perspectives to become a pharmaceutical company focused on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. Effective December 28, 2022, the Company acquired Soin Therapeutics LLC, a Delaware limited liability company (“STLLC”), and its patented product, a novel formulation of low-dose naltrexone, (“JAN123”). The product is being initially developed for the treatment of Complex Regional Pain Syndrome (CRPS), an indication that causes severe, chronic pain generally affecting the arms or legs. At present, there are no truly effective treatments for CRPS. The FDA has granted JAN123 Orphan Drug Designation for treatment of CRPS. This designation will provide the Company with tax credits for its clinical trials, exemption of user fees, and the potential of seven years of market exclusivity following approval. In addition, development of orphan drugs currently also involves smaller trials and quicker times to approval. However, there can be no assurance that the product will receive FDA approval or that it will result in material sales.
Fintech
On May 15, 2024, the Company acquired ALT5 Sigma, Inc. (“ALT5 Subsidiary”). ALT5 Subsidiary is a fintech company that provides next generation blockchain-powered technologies to enable a migration to a new global financial paradigm. ALT5 Subsidiary, through its respective subsidiaries, offers two main platforms to its customers: “ALT5 Pay” and “ALT5 Prime.” ALT5 Pay is a crypto-currency payment gateway that enables registered and approved global merchants to accept and make crypto-currency payments or to integrate the ALT5 Pay payment platform into their application or operations using the plugin with WooCommerce and or ALT5 Pay’s checkout widgets and APIs. Merchants have the option to convert to fiat currency (US Dollars, Canadian Dollars, Euros, and British Pounds Sterling) automatically or to receive their payment in digital assets (see Note 3).
Recycling
ARCA Recycling was the Company’s Recycling segment and provides turnkey recycling services for electric utility energy efficiency programs in the United States. ARCA Canada Inc. (“ARCA Canada”) provides turnkey recycling services for electric utility energy efficiency programs in Canada. Customer Connexx, LLC (“Connexx”) provides call center services for ARCA Recycling and ARCA Canada. On March 9, 2023, retroactive to March 1, 2023, the Company entered into a Stock Purchase Agreement with VM7 Corporation, a Delaware corporation, under which the Buyer agreed to acquire all of the outstanding equity interests of (a) ARCA Recycling, Inc., a California corporation, (b) Customer Connexx LLC, a Nevada limited liability company, and (c) ARCA Canada Inc., a corporation organized under the laws of Ontario, Canada (“ARCA Canada”; and, together with ARCA and Connexx, the “Subsidiaries”). The principal of the Buyer is Virland A. Johnson, our Chief Financial Officer. The sale of all of the outstanding equity interests of the Subsidiaries to the Buyer under the Purchase Agreement was consummated simultaneously with the execution of the Purchase Agreement. The Company’s Board of Directors unanimously approved the Purchase Agreement and the Disposition Transaction. In connection with the disposition of ARCA Recycling, accounts for the Recycling segment have been presented as discontinued operations in the accompanying consolidated financial statements (see Note 4).
8

Table of Contents
The Company reports on a 52- or 53-week fiscal year. The Company’s 2023 fiscal year (“2023”) ended on December 30, 2023, and the current fiscal year (“2024”) will end on December 28, 2024.
Going concern
The accompanying financial statements have been prepared under the assumption that the Company will continue as a going concern. Such assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of business, however, the issues described below raise substantial doubt about the Company’s ability to do so.
The Company currently faces a challenging competitive environment and is focused on improving its overall profitability, which includes managing expenses. The Company reported a net loss from continuing operations of approximately $2.4 million for the 39 weeks ended September 28, 2024. Additionally, as of September 28, 2024, the Company has total current assets of approximately $31.9 million and total current liabilities of approximately $42.3 million resulting in a net negative working capital of approximately $10.4 million. Cash provided by operations from continuing operations was approximately $3.7 million. Additionally, stockholders’ equity, as of September 28, 2024, is approximately $20.2 million.
The Company intends to raise funds to support future development of JAN 123 and JAN 101 and through a combination of cash flows derived from its acquisition of ALT5 (see Note 3), capital raises, and/or structured arrangements. However, the success of such funding cannot be assured.
Note 2: Summary of Significant Accounting Policies
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the U.S. (“U.S. GAAP”) and with the instructions to Form 10-Q and Article 10 of Regulation S-X for interim financial information. Accordingly, these financial statements do not include all of the information and notes required for complete financial statements prepared in conformity with U.S. GAAP. In our opinion, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. However, the Company’s results of operations for the interim periods presented are not necessarily indicative of the results that may be expected for the full year. For further information, refer to the consolidated financial statements and notes thereto included in our Form 10-K for the fiscal year ended December 30, 2023.
Principles of Consolidation
The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
Reclassifications
Certain amounts in the prior period have been reclassified to conform to the current period presentation. These reclassifications have no material effect on the reported financial results.
Use of Estimates
The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumption that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Significant estimates made in connection with the accompanying consolidated financial statements include the fair value in connection with the Series S convertible preferred stock issued in the Soin merger, the Series B Preferred Stock and Series M Preferred Stock issued in the transaction, pursuant to which the Company acquired the ALT5 Subsidiary, valuation allowance against deferred tax assets, and estimated useful lives for intangible assets.
Financial Instruments
Financial instruments consist primarily of cash equivalents, trade and other receivables, and obligations under accounts payable, accrued expenses and notes payable. The carrying amounts of cash equivalents, trade receivables and other receivables, accounts payable, accrued expenses and short-term notes payable approximate fair value because of the short maturity of these instruments.
9

Table of Contents
Digital Assets and other Receivables
Digital assets and other receivables are the Company’s digital assets and its customer prepayments in the form of digital assets. The Company holds all digital assets in secure non-custodial wallets through the wallet services from Fireblocks. As of September 28, 2024, the outstanding balance of digital assets and other receivables was approximately $20.9 million.
Digital Assets and other Payables
Digital assets and other payables are liabilities that represent the Company’s obligation to deliver the settlement of transactions in the form of digital assets and or cash. The Company safeguards these digital assets and cash for customers and is obligated to safeguard them from loss, theft, or other misuse. The Company recognizes digital assets and other payables, on initial recognition and at each reporting date, at fair value of the digital assets. Any loss, theft, or other misuse would impact the measurement of digital assets and other payables. As of September 28, 2024, the outstanding balance of digital assets and other payables was approximately $28.8 million.
Revenue Recognition
Revenue recognition applies to the Company’s Fintech segment only, as the Company’s Biotech segment has not recognized revenue to date. Revenue is recognized under Topic 606 in a manner that reasonably reflects the delivery of its services and products to customers in return for expected consideration and includes the following elements:
1.Executed contracts with the Company’s customers that it believes are legally enforceable;
2.Identification of performance obligations in the respective contract;
3.Determination of the transaction price for each performance obligation in the respective contract;
4.Allocation of the transaction price to each performance obligation; and
5.Recognition of revenue only when the Company satisfies each performance obligation.
These five elements, as applied to each of the Company’s revenue category, is summarized below:
1.Product sales – revenue is recognized at the time of sale of equipment to the customer.
2.Service sales – revenue is recognized based on when the service has been provided to the customer.
The Company’s service is comprised of a single performance obligation to buy and sell or convert digital assets to currencies. That is, the Company is the counter party to all transactions between customers and liquidity providers and presents revenue for the fees earned on a net basis.
The Company is acting as principal in all transactions, and control the digital assets being provided before it is transferred to the buyer, and has risk related to the digital assets, and is responsible for the fulfillment of the digital asset transactions. The Company sets the price for the digital assets by aggregating prices from several liquidity providers and displays them on the Company’s platform. As a result, the Company acts as a price discovery service and acts as a principal facilitating the ability for a customer to purchase or sell digital assets.
The Company considers its performance obligation satisfied, and recognizes revenue, at the point in time the transaction is processed. Contracts with customers are usually open-ended and can be terminated by either party without a termination penalty. Therefore, contracts are defined at the transaction level and do not extend beyond the service already provided.
The Company charges a fee at the transaction level. The transaction price, represented by the trading fee, is calculated based on volume and varies depending on payment type and the value of the transaction. Digital asset purchases or sale transactions executed by a customer on the Company’s platform is based on tiered pricing that is driven primarily by transaction volume processed for a specific historical period. The Company has concluded that this volume-based pricing approach does not constitute a future material right since the discount is within a range typically offered to a class of customers with similar volume. The transaction fee is collected from the customer at the time the transaction is executed. In certain instances, the transaction fee can be collected in digital assets, with revenue measured based on the amount of digital assets received and the fair value of the digital assets at the time of the transaction. The Company also marks up or down the digital asset prices and earns revenue from the spread between the buying and selling price. The Company also earns a fee from transfers of currencies and or digital assets. The transfer fees are nominal and are set to offset the fees associated with banking and or blockchain mining fees.
10

Table of Contents
Stock-Based Compensation
The Company from time to time grants stock options to employees, non-employees and Company executives and directors. Such awards are valued based on the grant date fair-value of the instruments. The value of each award is amortized on a straight-line basis over the vesting period.
Recently Issued Accounting Pronouncements
In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”). ASU 2023-07 requires, among other updates, enhanced disclosures about significant segment expenses that are regularly provided to the CODM, as well as the aggregate amount of other segment items included in the reported measure of segment profit or loss. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, and requires retrospective adoption. Early adoption is permitted. The Company is evaluating the impact of this guidance on its consolidated financial statements and related disclosures.
In December 2023, the FASB issued ASU No. 2023-08, Intangibles—Goodwill and Other—Crypto Assets (Subtopic 350-60): Accounting for and Disclosure of Crypto Assets. The amendments in ASU No. 2023-08 are intended to improve the accounting for certain crypto assets by requiring an entity to measure those crypto assets at fair value each reporting period with changes in fair value recognized in net income. The amendments also improve the information provided to investors about an entity’s crypto asset holdings by requiring disclosure about significant holdings, contractual sale restrictions, and changes during the reporting period. The amendments are effective for all entities for fiscal years beginning after December 15, 2024, including interim periods within those fiscal years. The Company is evaluating the impact of this guidance on its consolidated financial statements and related disclosures.
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”). ASU 2023-09 requires enhanced annual disclosures regarding the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, and may be adopted on a prospective or retrospective basis. Early adoption is permitted. The Company is evaluating the impact of this guidance on its consolidated financial statements and related disclosures.
Note 3: Mergers and Acquisitions
ALT5
On May 15, 2024, the Company acquired its ALT5 Subsidiary, which is a fintech company that provides next generation blockchain-powered technologies to enable a migration to a new global financial paradigm. ALT5 Subsidiary, through its respective subsidiaries, offers two main platforms to its customers: “ALT5 Pay” and “ALT5 Prime.” ALT5 Pay is a crypto-currency payment gateway that enables registered and approved global merchants to accept and make crypto-currency payments or to integrate the ALT5 Pay payment platform into their application or operations using the plugin with WooCommerce and or ALT5 Pay’s checkout widgets and APIs. Merchants have the option to convert to fiat currency (US Dollars, Canadian Dollars, Euros, and British Pounds Sterling) automatically or to receive their payment in digital assets.
As consideration under the acquisition, the Company issued 1,799,100 shares of its common stock to the legacy equity holders of the capital stock of ALT5 Subsidiary. Those shares represented approximately 19.9% of the Company's then-issued and outstanding shares of common stock. Each of the shares of the Company's newly-issued common stock was valued at $4.14, which was the Nasdaq Historical NOCP on Thursday, May 9, 2024, the day immediately prior to the date on which the agreement was executed. The Company also issued 34,207 shares of its newly-designated Series B Preferred Stock (the “Series B Stock”) to the legacy equity holders of the capital stock of ALT5. In connection with the closing of the
11

Table of Contents
acquisition of ALT5 Subsidiary, the Company also issued 3,200 shares of its newly-designated Series M Preferred Stock (the “Series M Stock”) to two entities that acted as finders for the transaction.
The fair value of the purchase price components outlined above was $16.0 million due to fair value adjustments for the shares of Series B Stock and Series M Stock, as detailed below (in $000’s):
Common stock$7,448 
Series B preferred stock8,552 
Total purchase price$16,000 
Under the preliminary purchase price allocation, the Company recognized goodwill of approximately $3.8 million, which is calculated as the excess of both the consideration exchanged and liabilities assumed as compared to the fair value of the identifiable assets acquired. The values assigned to the assets acquired and liabilities assumed are based on their estimates of fair value available as of May 10, 2024, as calculated by an independent third-party firm. Because the transaction was considered a stock purchase for tax purposes, none of the goodwill arising from the acquisition will be deductible for tax purposes. During the thirteen weeks ended September 28, 2024, the Company recorded a noncash fair value adjustment related to deferred tax liabilities in the aggregate amount of approximately $3.9 million, which was recorded to goodwill. The table below outlines the purchase price allocation of the purchase for ALT5 Subsidiary to the acquired identifiable assets, liabilities assumed and goodwill (in $000’s):
Total purchase price$16,000 
Accounts payable 267 
Digital assets payable16,763 
Debt7,613 
   Total liabilities assumed24,643 
Total consideration40,643 
Cash5,853 
Accounts receivable2,917 
Digital assets receivable9,082 
Intangible assets
Customer relationships$13,925 
Trade names2,675 
Developed technology1,850 
Subtotal intangible assets18,450 
Other492 
Total assets acquired36,794 
Total goodwill$3,849 
and an
Proforma Information
The table below presents selected proforma information for the Company for the thirteen and twenty-six week periods ended September 28, 2024, assuming that the acquisition had occurred on January 1, 2023 (the beginning of the Company’s 2023 fiscal year), pursuant to ASC 805-10-50 (in $000’s). This proforma information does not purport to
12

Table of Contents
represent what the actual results of operations of the Company would have been had the acquisition occurred on that date, nor does it purport to predict the results of operations for future periods.
As ReportedAdjustmentsProforma
ALT5 Sigma Corporation Unaudited 13 weeks ended September 28, 2024ALT5 Subsidiary Unaudited 13 weeks ended September 28, 2024Adjustments(1)ALT5 Sigma Corporation for the 13 weeks ended September 28, 2024
Net revenue$4,941 $ $4,941 
Net income$(822)$ $ $(822)
Earnings per basic common share$(0.06)$0.10 
Earnings per basic diluted share$(0.06)$0.10 
As ReportedAdjustmentsProforma
ALT5 Sigma Corporation Unaudited 13 weeks ended September 30, 2023ALT5 Subsidiary Unaudited 13 weeks ended September 30, 2023Adjustments(1)ALT5 Sigma Corporation for the 13 weeks ended September 30, 2023
Net revenue$ $1,657 $1,657 
Net income$(214)$953 $(537)$202 
Earnings per basic common share$(0.05)$0.05 
Earnings per basic diluted share$(0.05)$0.05 
As ReportedAdjustmentsProforma
ALT5 Sigma Corporation Unaudited 39 weeks ended September 28, 2024ALT5 Subsidiary Unaudited 39 weeks ended September 28, 2024Adjustments(1)ALT5 Sigma Corporation for the 39 weeks ended September 28, 2024
Net revenue$7,110 $2,918 $10,028 
Net income$(2,377)$71 $(806)$(3,112)
Earnings per basic common share$(0.24)$(0.36)
Earnings per basic diluted share$(0.24)$(0.36)
As ReportedAdjustmentsProforma
ALT5 Sigma Corporation Unaudited 39 weeks ended September 30, 2023ALT5 Subsidiary Unaudited 39 weeks ended September 30, 2023Adjustments(1)ALT5 Sigma Corporation for the 39 weeks ended September 30, 2023
Net revenue$ $4,912 $4,912 
Net income$9,993 $2,345 $(1,611)$10,727 
Earnings per basic common share$2.71 $2.91 
Earnings per basic diluted share$2.71 $2.91 
(1)Adjustments are related to adjustments made for the following:
Amortization expense of definite-lived intangible assets has been adjusted based on the preliminary fair value at the acquisition date.
13

Table of Contents
Soin Pharmaceuticals
Effective January 24, 2024, the Company, Amol Soin (“Dr. Soin”), and Soin Therapeutics LLC, a wholly-owned subsidiary of the Company that was had acquired from Dr. Soin, entered into an amendment (the “Soin Amendment”) to the parties’ Agreement and Plan of Merger that was dated as of December 28, 2022 (the “Soin Agreement”). With reference to the Soin Agreement, the parties to the Soin Amendment agreed that the $3.0 million convertible tranche (the first of the three original conversion tranches under the Soin Agreement) would be payable to Dr. Soin in cash rather than through his conversion of shares of the Series S Convertible Preferred Stock (the “Soin Preferred”) that constituted the consideration under the Soin Agreement. We tendered the first $100,000 amended tranche cash payment to Dr. Soin in March 2024; the second amended tranche cash payment to Dr. Soin, also in the amount of $100,000, is due on July 1, 2024; and the third amended tranche cash payment to Dr. Soin, in the amount of $2.8 million, is due on December 31, 2024. During the pendency of the amended cash tranche period, Dr. Soin agreed that he would not convert any of his shares of Soin Preferred. After we have tendered the second and third amended tranche cash payments to Dr. Soin, his conversion rights for the second and third original conversion tranches will remain convertible under the original provisions of the Soin Agreement and the related Certificate of Designation for the Soin Preferred. If we do not tender the second and third amended tranche cash payments to Dr. Soin, we agreed that we will transfer to him the membership interests of Soin Therapeutics LLC, and he will transfer to us the shares of Soin Preferred for cancellation.
In connection with the Soin Amendment, the Company reclassified the $3.0 million convertible tranche, originally valued at approximately $2.7 million on our balance sheet, from mezzanine equity to current liabilities, and reclassified the $10.0 million convertible tranche, originally valued at approximately $8.0 million on our balance sheet, to permanent equity. As of September 28, 2024, the outstanding balance in mezzanine equity relates to the $17.0 million convertible tranche originally valued at approximately $3.9 million.
Note 4: Discontinued Operations
On March 9, 2023, the Company discontinued operations of its Recycling segment as follows:
On March 9, 2023, the Company executed a Stock Purchase Agreement with VM7 Corporation, a Delaware corporation, under which, as of March 1, 2023, the Buyer agreed to acquire all of the outstanding equity interests of (a) ARCA Recycling, Inc., a California corporation, (b) Customer Connexx LLC, a Nevada limited liability company, and (c) ARCA Canada Inc., a corporation organized under the laws of Ontario, Canada (“ARCA Canada”; and, together with ARCA and Connexx, the “Subsidiaries”). The principal of the Buyer is Virland A. Johnson, our Chief Financial Officer. The sale of all of the outstanding equity interests of the Subsidiaries to the Buyer under the Purchase Agreement was consummated simultaneously with the execution of the Purchase Agreement. As of September 28, 2024 and December 30, 2023, no Recycling assets or liabilities were included in discontinued operations.
In accordance with the provisions of ASC 205-20, the Company has not included in the results of continuing operations the results of operations of the discontinued operations in the consolidated statements of operations and comprehensive income (loss). The results of operations for these entities for the 39 weeks ended September 28, 2024 and September 30, 2023 have been reflected as discontinued operations in the consolidated statements of operations and comprehensive income (loss) and consist of the following:
14

Table of Contents
13 weeks ended39 Weeks Ended
September 28, 2024September 30, 2023September 28, 2024September 30, 2023
Revenues$ $ $ $3,795 
Cost of revenues   3,992 
Gross profit   (197)
Operating expenses from discontinued operations:
Selling, general and administrative expenses$ $  1,468 
Gain on sale of ARCA   (15,824)
Total operating expenses from discontinued operations   (14,356)
Operating income from discontinued operations   14,159 
Other income (expense) from discontinued operations
Interest expense, net   (181)
Other income expense, net   (2)
Total other income (loss), net  $ $(183)
Income before provision for income taxes from discontinued operations   13,976 
Income tax provision (benefit) (28) 3,158 
Net income from discontinued operations$ $28 $ $10,818 
In accordance with the provisions of ASC 205-20, the Company has separately reported the cash flow activity of the discontinued operations in the consolidated statements of cash flows. The cash flow activity from discontinued operations for the 39 weeks ended September 28, 2024 and September 30, 2023 have been reflected as discontinued operations in the consolidated statements of cash flows and consist of the following:
15

Table of Contents
39 weeks ended
September 28, 2024September 30, 2023
DISCONTINUED OPERATING ACTIVITIES:
Net income from discontinued operations 10,818 
Depreciation and amortization 96 
Amortization of debt issuance costs 11 
Amortization of right-of-use assets 53 
Change in deferred taxes 3,157 
Gain on sale of ARCA, net of cash (15,967)
Gain on sale of GeoTraq  
Changes in assets and liabilities:
Accounts receivable 2,932 
Inventories 299 
Prepaid expenses and other current assets 55 
Accounts payable and accrued expenses 866 
Net cash provided by operating activities from discontinued operations$ $2,320 
DISCONTINUED INVESTING ACTIVITIES:
Purchases of property and equipment (123)
Purchase of intangible assets (33)
Net cash used in investing activities from discontinued operations$ $(156)
DISCONTINUED FINANCING ACTIVITIES:
Proceeds from note payable 5,162 
Payment on related party note (38)
Proceeds from issuance of short-term notes payable (7,291)
Payments on notes payable (45)
Net cash used in financing activities from discontinued operations$ $(2,212)
Effect of changes in exchange rate on cash and cash equivalents (5)
DECREASE IN CASH AND CASH EQUIVALENTS (53)
CASH AND CASH EQUIVALENTS, beginning of period 53 
CASH AND CASH EQUIVALENTS, end of period$ $ 
Note 5: Trade and other receivables
The Company’s trade and other receivables as of September 28, 2024 and December 30, 2023, respectively, were as follows (in $000’s):
September 28,
2024
December 30,
2023
Trade receivables853  
Interest receivable - SPYR 266 
Other receivables50  
Trade and other receivables, net$903 $266 
During the three months ended September 28, 2024, the Company was notified that SPYR Technologies, Inc. (“SPYR”) had ceased operations, and that no future quarterly interest payments on the promissory note for the Company’s sale of its subsidiary GeoTraq, Inc. would be made. Consequently, the Company has recorded an allowance of approximately $250,000 against the existing balance in accounts receivable related to SPYR’s interest payments.
16

Table of Contents
Note 6: Prepaids and other current assets
Prepaids and other current assets as of September 28, 2024 and December 30, 2023 consist of the following (in $000’s):
September 28,
2024
December 30,
2023
Prepaid consulting agreements$1,149 $3 
Prepaid insurance3 72 
Prepaid other285  
Total prepaid expenses and other current assets$1,437 $75 
Note 7: Property and Equipment
Property and equipment as of September 28, 2024 and December 30, 2023 consist of the following:
September 28, 2024December 30, 2023
Projects under construction$1,170 $ 
Total property and equipment, net$1,170 $ 
The Company recorded no depreciation expense from continuing operations for the 39 weeks ended September 28, 2024 and September 30, 2023.
Note 8: Leases
In connection with its acquisition of ALT5 Subsidiary (see Note 3), the Company leases commercial office space. These assets and properties are leased under noncancelable agreements that expire at various future dates. The agreements, which have been classified as operating leases, provide for minimum rent and require the Company to pay all insurance, taxes, and other maintenance costs. As a result, the Company recognizes assets and liabilities for leases with lease terms greater than 12 months. The amounts recognized reflect the present value of remaining lease payments for all leases. The discount rate used is an estimate of the Company’s blended incremental borrowing rate based on information available associated with each subsidiary’s debt outstanding at lease commencement. In considering the lease asset value, the Company considers fixed and variable payment terms, prepayments and options to extend, terminate or purchase. Renewal, termination, or purchase options affect the lease term used for determining lease asset value only if the option is reasonably certain to be exercised.
The following table details the Company’s right of use assets and lease liabilities as of September 28, 2024 and December 30, 2023 (in $000’s):
September 28, 2024December 30, 2023
Right of use asset - operating leases$120 $ 
Lease liabilities:
Current - operating26  
Long term - operating94  
As of September 28, 2024, the weighted average remaining lease term for operating leases is 2.4 years. The Company’s weighted average discount rate for operating leases is 11.0%. Total cash payments for operating leases for the 39 weeks ended September 28, 2024 was approximately $19,000. No cash payments for operating leases were made during the 39
17

Table of Contents
weeks ended September 30, 2023. Additionally, the Company recognized approximately $134,000 in right of use assets and liabilities upon commencement of operating leases during the 39 weeks ended September 28, 2024.
Total present value of future lease payments of operating leases as of September 28, 2024 (in $000’s):
Twelve months ended
2025$57 
202657 
202724 
Total138 
Less implied interest(18)
Present value of payments$120 
Note 9: Intangible Assets
Intangible assets as of September 28, 2024 and December 30, 2023 consist of the following (in $000’s):
September 28,
2024
December 30,
2023
Soin intangibles *$19,293 $19,293 
Customer relationships13,925  
Trade names2,675  
Developed technology1,850  
Patents and domains$4 $4 
Intangible assets37,747 19,297 
Less accumulated amortization(3,770)(1,451)
Total intangible assets$33,977 $17,846 
*The Soin intangibles acquired by the Company consist of the following:
1.Two pending patents and one approved patent related to the methods of using low-dose Naltrexone to treat chronic pain;
2.Final formula for Naltrexone; and
3.Orphan drug designation as approved by the FDA.
Intangible amortization expense was $2.1 million and $363,000 for the 13 weeks ended September 28, 2024 and September 30, 2023 and $2.3 million and $1.1 million for the 39 weeks ended September 28, 2024 and September 30, 2023.
18

Table of Contents
Note 10: Marketable Securities
Marketable securities in connection with SPYR’s acquisition of GeoTraq consist of the following (in $000’s, except shares):
Series G Convertible Preferred SharesCommon Shares EquivalentAmount
Beginning Balance, December 30, 20239,224952,442,000$286 
Securities received8,469846,900,00084 
Mark-to-market(190)
Ending Balance, March 30, 202417,6931,799,342,000180 
Securities received25,40725,407,000,000434 
Mark-to-market(180)
Ending Balance, June 29, 202443,10027,206,342,000$434 
Write off of marketable securities(434)
Ending Balance, September 28, 2024$ 
During the three months ended September 28, 2024, the Company was notified that SPYR Technologies, Inc. (“SPYR”) had ceased operations, and that no future quarterly interest payments on the promissory note, which may be remitted in either restricted shares of common stock or restricted shares of Series G Convertible Preferred Stock of SPYR, or in cash, would be made. Consequently, the Company has recorded a full write-off of approximately $434,000 of its Series G Convertible Preferred shares of SPYR.
Note 11: Deposits and Other Assets
Deposits and other assets as of September 28, 2024 and December 30, 2023 consist of the following (in $000’s):
September 28,
2024
December 30,
2023
Other 9 
Total deposits and other assets$ $9 
Note 12: Accrued Liabilities
Accrued liabilities as of September 28, 2024 and December 30, 2023 consist of the following (in $000’s):
September 28,
2024
December 30,
2023
Compensation and benefits$80 $37 
Accrued guarantees1,209 3,049 
Accrued legal472